Spots Global Cancer Trial Database for A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis
Official Title: A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis
Study ID: NCT02718300
Conditions
Study Description
Brief Summary: The purpose of this study is to evaluate the safety, tolerability, and efficacy of the combination of parsaclisib and ruxolitinib in subjects with myelofibrosis.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Birmingham Hematology & Oncolgy Associates Llc, Birmingham, Alabama, United States
Mayo Clinic Arizona, Scottsdale, Arizona, United States
Alta Bates Medical Center, Berkeley, California, United States
City of Hope National Medical Center, Duarte, California, United States
California Cancer Associates For Research and Excellence, Fresno, California, United States
University of Southern California, Los Angeles, California, United States
UCLA School of Medicine, Los Angeles, California, United States
Pcr Oncology, Pismo Beach, California, United States
California Cancer Assoc. for Research and Excellence, San Marcos, California, United States
Georgetown University Hospital, Washington, District of Columbia, United States
Shands Hospital, Gainesville, Florida, United States
Emory University, Atlanta, Georgia, United States
University of Chicago Medical Center, Chicago, Illinois, United States
Indiana Blood and Marrow Transplantation, Indianapolis, Indiana, United States
McFarland Clinic, Ames, Iowa, United States
University of Kansas Cancer Center, Westwood, Kansas, United States
Norton Cancer Institute, Louisville, Kentucky, United States
Saint Agnes Hospital, Baltimore, Maryland, United States
Cancer Center For Blood Disorders, Bethesda, Maryland, United States
Massachusetts General Hospital, Boston, Massachusetts, United States
Washington University School of Medicine, Saint Louis, Missouri, United States
Summit Medical Group, Florham Park, New Jersey, United States
Hackensack University Medical Center, Hackensack, New Jersey, United States
New Mexico Cancer Care Alliance, Albuquerque, New Mexico, United States
Montefiore Medical Center, Bronx, New York, United States
Roswell Park Cancer Institute, Buffalo, New York, United States
Mount Sinai School of Medicine, New York, New York, United States
Columbia University Medical Center, New York, New York, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Oncology Hematology Care, Inc., Cincinnati, Ohio, United States
Cleveland Clinic, Cleveland, Ohio, United States
Oregon Health & Science University, Portland, Oregon, United States
Rush University Medical Center, Nashville, Tennessee, United States
Baylor Scott and White Research Institute, Dallas, Texas, United States
Md Anderson Cancer Center, Houston, Texas, United States
Cancer Care Centers of South Texas, San Antonio, Texas, United States
Renovatio Clinical Consultants Llc, The Woodlands, Texas, United States
Va Salt Lake City Health Care System, Salt Lake City, Utah, United States
Vista Oncology Inc Ps, Olympia, Washington, United States
Contact Details
Name: Albert Assad, MD
Affiliation: Incyte Corporation
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
